1997 by the Bureau of the Census indicate that 16.8% of full-time workers are shift workers, including 3.5% working a steady night shift and 2.9% working rotating shifts. 1 Night work is associated with impaired alertness, decreased performance, disturbed sleep, and an increased rate of accidents. 2-4 Among rotating-shift workers, 53% report falling asleep during the night shift at least once each week, in contrast to 23% of rotating workers on the day shift, and 8% of permanent day workers. 5 A study using ambulatory electroencephalogram (EEG) recordings indicated that 20% of shift workers fell asleep during a single night shift, whereas none slept during the afternoon/evening shift. 3 Human performance also declines to its lowest in the early morning for most skills. 6-8 Impaired alertness and performance associated with night-shift work have contributed to an increased risk of accidents in the transportation industry, 9-13 as well as to industrial disasters such as the Exxon-Valdez oil spill 14 and the Chernobyl nuclear power-plant meltdown. 15, 16 Sleepiness on the night shift is caused by (1) the desynchrony between circadian sleep tendency and the schedule of sleep and wakefulness required by night work and (2) cumulative sleep deprivation. Extension of daytime sleep via napping 17, 18 or use of hypnotic medication 19,20 may mildly reduce the severity of sleepiness and performance on the night shift, but significant impairments remain. The use of caffeine 20,21 and methamphetamine 23 have also been shown to reduce sleepiness, performance impairment, and negative mood associated with simulated night shifts.
Study Objectives: To assess the effect of 200 mg of modafinil compared to placebo on alertness, neurobehavioral performance, and executive function during 4 consecutive simulated night shifts. Design: Double-blind, randomized, parallel groups. Setting: Sleep research facility. Participants: 32 male and female volunteers between the ages of 18 and 55 years. Interventions: 200 mg of modafinil or placebo given nightly on the 4 consecutive simulated night shifts. Measurements and Results: Subjects were randomly assigned to 1 of the 2 treatment conditions, following medical, psychiatric, and polysomnographic screening. On 4 consecutive nights, subjects took study drug at 2200, and then from about 2300 to 0730 participated in a simulated night shift that included the Maintenance of Wakefulness Test, Psychomotor Vigilance Test, Digit Symbol Substitution Test, measures of subjective alertness, and multiple executive-function measures. At 0800, daytime sleep periods were recorded polysomnographically for 6 to 8 hours. Alertness-as measured by the MWT, vigilance and reaction time as indexed by Psychomotor Vigilance Test lapses, and slowest 10% of reaction times-and 3 executive-function tasks showed significant enhancement with modafinil versus placebo. Subjective sleepiness at night and some performance measures did not show consistent treatment differences. Daytime sleep showed minimal differences between conditions. Conclusions: The physiologic sleepiness and neurobehavioral deficits that occurred during the hours of a typical night shift were clearly attenuated by modafinil. Modafinil also had beneficial effects on some measures of executive function. Citation: Walsh JK; Randazzo AC; Stone KL; Schweitzer PK. Modafinil improves alertness, vigilance, and executive function during simulated night shifts. SLEEP 2004;27(3):434-9.
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with the study protocol. Screening procedures included medical history, physical examination, routine hematology and urinalysis, psychological screening including the Zung Anxiety and Depression Scales, urine drug screen, and pregnancy test (for women). Based on these procedures, subjects were excluded if they had any uncontrolled chronic or acute medical, neurologic, or psychiatric illness; had a history of drug abuse or alcoholism; used central nervous system-active medication; kept an irregular sleep schedule, (eg, shift work); routinely consumed more than 400 mg of caffeine daily; or were pregnant or breastfeeding. Screening polysomnography was performed to exclude those with sleep apnea (apnea-hypopnea index ≥ 10) or periodic limb movement disorder (periodic limb movement index with arousal ≥ 10), as was a multiple sleep latency test (MSLT) the following day to exclude individuals with severe sleepiness (mean latency ≤ 5 minutes).
Thirty-nine subjects were screened for the study. Seventeen failed screening (3 failed the drug screen; 4 failed the MSLT; 5 were disqualified because of abnormal laboratory results, medical history, physical examination, or use of concomitant medication; and 5 withdrew for personal reasons). A total of 22 individuals was randomly assigned to receive modafinil or placebo, including 3 replacements for individuals who did not complete study participation. Inability to fulfill obligations of the study (because of job interview, ill family member, meeting attendance) was the reason 2 subjects in the modafinil group and 1 in the placebo group did not complete the study. No subject discontinued because of an event related to study drug. The present report includes the 19 subjects who completed the protocol (16 assigned to modafinil, 3 to placebo) and data from 13 subjects randomly assigned to placebo in a simultaneous study with an identical design (examining caffeine versus placebo) and identical entry criteria. Neither the 19 subjects enrolled in this protocol nor study staff involved in the scoring of data knew the proportion of subjects to be assigned to modafinil or placebo. The final sample for this study included 32 subjects (16 in each group). There were no group differences in age (modafinil mean age = 29.7 ± 13.2 years; placebo mean age = 33.2 ± 11.4 years; t = -.790, P = .436) or sex (modafinil = 7 men, 9 women; placebo = 10 men, 6 women; χ 2 = 1.129, P = .288).
Training for all tests and questionnaires to be used in the study occurred during an initial office visit and during the day of the MSLT. Individuals who met all screening criteria were instructed to sleep 8 hours or more per night, with bedtime at their habitual bedtime ± 1 hour, for a minimum of 1 week prior to randomization. Subjects kept daily sleep logs and were monitored via actigraphy (Actiwatch, Mini-Mitter, Bend, OR) to encourage compliance but were not excluded if they did not follow instructions.
Experimental Design, Methods, and Measures
Each subject participated in a 4-night, 4-day simulated night-shift schedule (see Figure 1 ). Subjects were randomly assigned to receive either placebo or 200 mg of modafinil in double-blind fashion, administered at 2200 nightly. From 2300 until approximately 0700, subjects participated in a variety of tasks, including the Maintenance of Wakefulness Test (MWT), the Psychomotor Vigilance Task (PVT), the Digit Symbol Substitution Test (DSST), and subjective measures including the Stanford Sleepiness Scale (SSS) and the Karolinska Sleepiness Scale. Each task was administered 4 times nightly at approximately 2-hour intervals. In addition, tests of executive function (which varied nightly) were conducted at 0215 and either 0415 or 0500 (counterbalanced between conditions). Following breakfast, a 30-minute period of sunlight exposure ensued (near a large window) to partially simulate the light exposure during a morning commute. Actual intensity of light exposure was not controlled or measured on each morning, but illumination measures in the location the subjects occupied, taken on multiple days, showed a range of approximately 500 to 1500 lux. Sleep was monitored polysomnographically each day, beginning between 0815 and 0830. Subjects slept in noise-attenuated, darkened, single rooms. Subjects slept ad libitum with the restriction that time in bed was a minimum of 6 hours and maximum of 8 hours. The minimum time in bed guarded against subjects prematurely terminating the study for personal reasons and imposing significant sleep restriction upon themselves. Since night-shift workers rarely sleep more than 8 hours during the day, the maximum time in bed was set at 8 hours.
Following each polysomnogram, subjects were free to leave the laboratory to carry out their usual activities. Typically subjects left the laboratory between 1500 and 1715 and returned at 2130 each night. They were instructed to avoid naps, not to use medications unless approved by the investigator, and to limit caffeine consumption to 1 cup or can of a caffeinated beverage per day. Compliance was monitored via actigraphy and daily diary. Food consumption, light exposure, and exercise were not controlled during the time away from the laboratory.
To promote a constant level of subject motivation over repeated nights of MWT testing, the criterion for termination (but not scoring) of each subtest was modified. Each 30-minute subtest of the MWT was conducted using standard procedures until the sleep-latency criterion was met. Terminating the test at that time (in accord with standard research MWT guidelines) could serve as a "reward" because it would end the aversive experience of fighting sleep during a time of intense sleep pressure. Instead, the test was extended by instructing subjects to "keep their eyes open" 2 to 5 times at the appearance of drowsiness or sleep. In this way, subjects were not "rewarded" for low motivation levels by terminating the test as soon as they fell asleep. This procedure continued to minimize the amount of sleep obtained during each subtest and avoided providing subjects with a cue that the test would be terminated if they fell asleep, which also could reduce motivation to stay awake. Mean latency to the first epoch of any sleep stage was the dependent measure. A latency of 30 minutes was recorded if a subject remained awake during the entire 30-minute subtest. The PVT is a computer-based reaction-time test requiring sustained attention that has been demonstrated to be sensitive to fluctuations in alertness in a variety of situations and conditions. 31 Each of the 4 nightly PVT presentations lasted 15 minutes. PVT-dependent measures were the frequency of lapses (the number of reaction times ≥ 500 milliseconds) and mean duration of the 10% slowest reaction times, a measure reflecting vigilance response slowing.
The 33 which involves communicating unusual and unique ideas through drawing. Night 4. Category Test, 37 Letter-Number Sequencing (LNS), 38 and Haylings Sentence Completion Test (SCT). 39 The Category Test measures the ability to identify connecting ideas or principles. LNS is a subtest of the Wechsler Memory Scale-III and is a test of working memory. SCT evaluates an individual's ability to resist closure and avoid perseveration. Baseline data were obtained for the Optimal Telegram, TTCT-V, and TTCT-F on the day of the screening MSLT, typically between the third and fourth MSLT subtests, approximately 6.5 to 7.5 hours after awakening (about 1330 to 1530).
Statistical Analysis
All data were scored without knowledge of treatment condition. Data analyses consisted of mixed-model analyses of variance (2 groups by 4 nights by 4 time points) for MWT, PVT, and most subjective measures; 2 groups by 4 days/nights for daytime sleep data and Optimal Telegram (change from baseline). The Huynh-Feldt adjustment was used to control for sphericity for within-subject factors. Follow-up analyses varied depending on the question of interest, the model, and the results of the omnibus ANOVA but typically involved examination of group differences on a nightly basis. Prior to undergoing ANOVA procedures, PVT lapses underwent square-root transformation to normalize distributions, compress large counts, and prevent scores of 0. Slowest 10% of responses on the PVT underwent reciprocal transformation to compress the range of scores. Multivariate ANOVAs were conducted on the difference scores (change from baseline) for the TTCT-V (2 groups, 3 variables) and the TTCT-F (2 groups, 5 variables), with follow-up t tests for between-group comparisons of each variable. T tests were conducted on the remaining executive-function tests.
RESULTS

Polysomnographic Data
Daytime polysomnography data are presented in Table 1 . ANOVA revealed no group difference or group by day interaction for total recording time; however, there was a decrease in total recording time across days (F 3,90 =16.4), P < .001). There were no differences in total sleep time between groups (F 1,30 = 0.26, P = .614) or across days (F 3,90 = 1.67, P = .18). Mean total sleep times for the 4 daytime sleep periods were 333.9 ± 54.7 minutes and 344.7 ± 65.1 minutes for the modafinil and placebo groups, respectively. Mean latency to persistent sleep (the first of 20 consecutive epochs of sleep) showed a trend (F 1,30 = 2.9, P = .097) for the placebo group to fall asleep slightly faster (mean for 4 days = 6.0 ± 4.8 minutes) than the modafinil group (8.9 ± 4.8 minutes). Sleep latency increased slightly, but significantly, across days (F 3,90 =5.5, P = .002) for both groups. There was no interaction. Notably, despite the fact that mean total recording time never exceeded 434.8 minutes, mean sleep efficiencies ranged from 77.0% to 84.2%, consistent with the frequently demonstrated reduction of sleep time when sleep is attempted during the day.
Except for a slight decrease in minutes of stage 1 sleep across the 4 days for both groups (F 3,90 = 3.7, P = .015), there were no significant group effects, day effects, or group by day interactions for any other absolute polysomnography variable. When sleep stages were evaluated as percentage of total sleep time, there was a group by day interaction (F 3,90 = 3.4, P = .03) for stage 3-4 sleep, with a greater percentage of stage 3-4 sleep on day 3 for the modafinil group compared to placebo (26.4% vs 15.3%, respectively, t = 2.8, P = .01). The main effect for group showed a trend (F 1,30 = 3.5, P = .072) for the modafinil group to have a higher percentage of stage 3-4 sleep.
MWT Data
Mean latencies to sleep onset for the MWT on each of the 4 nights are shown in Figure 2 . Table 2 shows the statistical results for the overall ANOVA. There was a significant main effect for group. Mean MWT latencies on the 4 nights were 23.8 ± 6.5, 21.9 ± 4.7, 24.1 ± 6.3, and 25.1 ± 5.4 minutes for the modafinil group, as compared to 15.0 ± 7.4, 19.5 ± 9.8, 19.2 ± 9.9, and 19.9 ± 10.7 minutes for the placebo group. Significant main effects were also found for night, and time of night, as well as significant interactions for time of night by group and night by time of night by group, with a trend for a night by group interaction. Polynomial contrasts indicated a strong linear decrease in MWT sleep latencies during the night, every night (F 1,30 =89.7, P < .001). Because of the night by time of night by group interaction, follow-up group comparisons were done at each time point for each night. On night 1, the modafinil group was significantly more alert than the placebo group at 0145, 0345 and 0630 (F 1,30 =12.775, 9.792, and 14.123, respectively, P < .01 for all). On night 2, there was a trend for modafinil subjects to be more alert at 0345 (F 1,30 =3.372, P = .076.) On night 3, the modafinil group was more alert at 0345 (F 1,30 = 7.804, P < .01), while on night 4, the modafinil group was more alert at 2345 (F 1,30 = 4.92, P = .034) with a trend at 0145 (F 1,30 = 3.219, P = .083).
Modafinil Improves
The placebo group displayed an increase in alertness across nights (F 1,15 = 8.09, P = .012) whereas the modafinil group maintained approximately the same level of alertness each night (F 3,45 = 1.315, P > .2).
In addition to analyzing group mean MWT data, the percentage of subjects with a mean MWT latency > 15 minutes was examined for each group. Averaging across nights 1 to 4, significantly more modafinil subjects (93.7%) met this criterion as compared to placebo subjects (62.5%; χ 2 = 4.6, P = .033). For nights 1 to 4 individually, the percentages of subjects in the modafinil group with a mean MWT latency > 15 minutes were 87.5%, 87.5%, 87.5%, and 93.7%, respectively, whereas for the placebo group, the comparable percentages were 43.8%, 68.8%, 75.0%, and 62.5%, respectively.
Performance Data
PVT Lapses
Mean PVT lapses by time of night are shown for each night in Figure  3 , and ANOVA results are shown in Table 2 . On each night, the mean number of lapses per night in the placebo group was between 40% and 200% higher than in the modafinil group. There were significant main effects for group, night, and time of night and significant interactions for time of night by group and night by time of night, plus a trend for a night by group interaction.
Polynomial contrasts indicated a significant increase in the frequency of lapses as the night progressed (F 1,30 = 42.634, P < .001). The placebo group made significantly more lapses than the modafinil group at 0315 and 0600 on night 1 (F 1,30 = 4.385, 6.412, respectively, P < .05), at 0315 and 0600 on night 3 (F = 6.216, 6.703, respectively, P < .02), and at all time points on night 4 (F = 4.926, 8.441, 6 .597, and 5.956, respectively, P < .04.)
The placebo group displayed an increase in the number of lapses across the 4 nights (F 3,45 = 6.149, P = .003), whereas the modafinil group maintained approximately the same level of lapses nightly (F 3,34 < 1, P > .5).
Slowest 10% Reaction Times on PVT
This variable showed results compatible with data on PVT lapses. There were main effects for group (F 1,30 =6.118, P = .019), night (F 3,90 = 3.832, P = .018), and time (F 3,90 = 36.909, P < .001), as well as interactions of time of night by group (F 3,90 = 5.232, P = .002) and night by time of night (F = 2.613, P = .016). The night by group interaction was not significant (F 3,90 = 2.070, P = .122. ) The placebo group had slower reaction times in this response domain than did the modafinil group at 0115, 0315, and 0600 on night 1 (F 1,30 = 12.119, 4 .655, 7.528, respectively, P < .04), at 0115, 0315, and 0600 on night 2 (F = 4.337, 7.178, 8.451, respectively, P < .05), and during all subtests on night 4 (F = 7.048, 8.517, 6.002, 6.809, respectively, P < .02).
Digit Symbol Substitution Test
There was a significant main effect of night for the DSST, indicating improvement in performance from night 1 to night 4 (F 3,87 = 19.365, P < .001), likely a practice effect. Performance decreased significantly across time of night (F 3,87 = 5.67, P = .002) for both groups. There was no main effect for group. The modafinil group completed a mean of 51.4, 55.5, 57.1, and 58.4 items on nights 1 through 4, respectively, as compared to 52.0, 54.6, 56.3, and 56.6 by the placebo group.
Subjective Sleepiness-Alertness
The SSS was completed prior to (SSS-a) and following (SSS-b) each of the 4 PVT sessions. SSS-a and SSS-b were analyzed separately. Both showed main effects for night (F 3,90 = 11.0 and 5.428, P < .002, respectively), with sleepiness declining across nights. There was also a significant increase in sleepiness across time of night (F 3,90 = 88.7 and 111.0, P < .001, respectively), and a night by group interaction (F 3,90 = 3.6 and 3.2, P < .03). Follow-up analyses showed a trend for the placebo group to be sleepier than the modafinil group on night 1 (F 1,30 = 3.9 and 2.8, P = .058 and .103, respectively.)
The Karolinska Sleepiness Scale showed main effects for night (F 3,90 = 3.5, P = .018) and time of night (F 3,90 = 90.1, P < .001), a trend for a night by group interaction (F 3,90 = 2.1, P = .10), and a night by time of night by group interaction (F 9,270 = 2.6, P = .01). The placebo group was sleepier than the modafinil group at the first time point on the first night (F 1,30 = 7.5, P = .01). However, the modafinil group was sleepier than the placebo group at the first time point on the third night ( Executive Function Figure 4 displays mean difference from baseline, expressed as standard scores, for the TTCT-V, which was conducted on night 1. Test performance was worse during the night shift compared to baseline (F 1,30 = 19.2, P < .001). Multivariate ANOVA on the change from baseline revealed an overall group difference (F 3,28 = 4.17, P = .015). Follow-up t tests showed that the placebo group performed more poorly than the modafinil group in the areas of verbal flexibility (t = -3.131, P = .004) and verbal originality (t = -2.492, P = .019). A trend in the same direction was seen for verbal fluency (t = -1.736, P = .093).
The mean numbers of total errors and of perseverative errors on the WCST from night 2, expressed as standard scores, are shown for each group in Figure 5 . Both counts of errors were significantly more frequent for the placebo group than for the modafinil group (t = 3.003, P = .006 and 2.097, P = .007, respectively). Errors on the SCT conducted on night 4 were also significantly different between groups (t = -2.083, P = .049). The mean number of errors was approximately 66% higher for the placebo group (mean = 7.47), as compared to the modafinil group (mean = 4.50).
The other executive-function assessments showed no significant main effects for group; in addition to the lack of a group effect, the Optimal Telegram did not show a main effect for night or an interaction.
DISCUSSION
Consistent attenuation of the physiologic and neurobehavioral deficits that occur during the hours of a typical night shift was demonstrated to occur with 200 mg of modafinil. Alertness, as measured by the MWT, and vigilance and reaction time, as indexed by the PVT, showed significant differences between groups, all in favor of modafinil. Additionally, 3 executive-function tasks demonstrated better performance with modafinil than with placebo. These findings are theoretically consistent with the premise that night shift-related errors and accidents would be reduced if similar effects of modafinil were to occur in actual shift workers. Recent preliminary reports 40, 41 indicate that modafinil significantly improved the alertness and neurobehavioral function of current shift workers meeting diagnostic criteria for shift work sleep disorder. However, in that study, dependent measures were made in a controlled laboratory environment, as opposed to actually evaluating errors and accidents in the work place. Further, the study sample was limited to shift workers meeting diagnostic criteria of shift work sleep disorder.
There was no clinically meaningful negative effect of modafinil on sleep during the day. Sleep disruption would be considered an adverse effect of modafinil use, particularly because circadian factors produce marked sleep disruption for most night-shift workers. No other significant side effects were reported by subjects. Interestingly, there was a trend for more stage 3-4 sleep in the modafinil group, the explanation for, and the significance of which, is unknown. If the tendency for more stage 3-4 sleep was a reflection of increased homeostatic sleep drive related to the wake-promoting impact of modafinil, one would also expect an increase in total sleep time, which was not found.
Our findings are consistent with the findings of a number of other investigations of modafinil as a countermeasure to sleepiness associated with circadian and/or homeostatic factors in normal individuals. For example, Caldwell et al 42 documented improved flight-simulator performance and enhanced alertness with modafinil in sleep-deprived helicopter pilots. During periods of sleep deprivation, modafinil has also been shown to improve performance on perceptual judgment, complex addition, and 4-choice reaction-time tasks. 43, 44 The significantly better performance with modafinil on the PVT, but not on the DSST, may in part be related to task duration. The PVT was 15 minutes in duration, whereas the DSST lasted 90 seconds. Task duration has long been known to be an important determinant of sleepinessrelated performance deficits. 45 The executive-function benefits of modafinil have recently been reported to be selective, rather than global, in terms of the specific domain of ability tested. 46 Whether those observations are related to the doses tested, or to the use of nonsleepy subjects, as opposed to true differential effects of the drug, cannot be determined with certainty. However, enhancement of adaptive response inhibition was one of the executive-function domains found to consistently improve with modafinil by Turner et al, 46 and in the present study, two of three tasks measuring response inhibition (WCST and SCT but not Category Test) were improved with modafinil. Reduction of impulsive and/or perseverative responding suggests potential benefit of modafinil for attentiondeficit/hyperactivity disorder. 46 More generally, what should be the role of wake-promoting agents in attempts to reduce the risks associated with work schedule-related sleepiness? Certainly this is a complex and challenging question requiring consideration from multiple viewpoints by many segments of society. 47 and employment and other obligations continue. For some of these situations, adding wake-promoting drugs to behavioral strategies would appear to be very appropriate. Research and clinical experience have proven modafinil to be well tolerated, with extremely rare serious adverse events. Nevertheless, given the lack of systematic study of modafinil in patients with hypertension, recent myocardial infarction, unstable angina, and other cardiovascular signs or abnormalities, the drug is not recommended for such individuals. Also, with the increased dopaminergic activity in common with amphetamines, prudence in assessment of risk-benefit ratio for each individual patient is suggested, even though abuse or dependence liability appears to be quite low.
A number of studies demonstrate that modafinil is reliably discriminated from, and has much lower abuse potential than, other stimulants such as cocaine, amphetamine, and methylphenidate. [49] [50] [51] [52] We conclude that the potential for reducing the risk of sleepiness-related accidents and injuries in shift workers with modafinil would appear to represent a favorable risk/benefit ratio in carefully selected and monitored individuals.
